The antiserum was produced against synthesized peptide derived from mouse KOR-1 around the phosphorylation site of Ser369. AA range:331-380

Phospho-KOR-1 (S369) Polyclonal Antibody detects endogenous levels of KOR-1 protein only when phosphorylated at S369.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):PAsMR

OPRK1

Kappa-type opioid receptor

OPRK1 ;
OPRK ;
Kappa-type opioid receptor ;
K-OR-1 ;
KOR-1

Endogenous opioid peptides and opiates, like morphine, transmit their pharmacological effects through membrane bound opioid receptors. Pharmacological studies and molecular cloning have led to the identification of three different types of opioid receptor, mu-type, delta-type and kappa-type, also designated MOR-1, DOR-1 and KOR-1, respectively. MOR-1 is a receptor for beta-endorphin, DOR-1 is a receptor for enkephalins, and KOR-1 is a receptor for dynorphins.The three opioid receptor types are highly homologous and belong to the superfamily of G-protein-coupled receptors. Opioid receptors have been shown to modulate a range of brain functions, including instinctive behavior and emotions. This regulation is thought to involve the inhibition of neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance.